Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Craniopharyngioma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Hypothalamic obesity in survivors has no reliable treatment; GLP-1 agonists, setmelanotide and oxytocin are in trials.
No systemic therapy is established for adamantinomatous tumours; IL-6 blockade and MEK inhibition (downstream of the beta-catenin-driven inflammatory programme) are being tested.
How long BRAF/MEK inhibition should continue in papillary tumours and whether radiotherapy can be omitted after response.
Recurrence after subtotal resection in children too young for radiotherapy.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Acquired hypothalamic obesity in adults and children aged 4 years and older
Least-squares mean change in body-mass index at 52 weeks minus 16.
BRAF plus MEK inhibition (vemurafenib-cobimetinib per Alliance A071601, or dabrafenib-trametinib) before or instead of extensive surgery; radiotherapy after response.
Vemurafenib plus cobimetinib produces responses in nearly all BRAF V600E papillary craniopharyngiomas (Lancet Oncology).
Chronic weight management in obesity due to POMC, PCSK1 or LEPR deficiency